Grunenthal gains rights to AcelRx's Zalviso in potential $250M deal

German firm Grunenthal secured the rights to commercialize AcelRx Pharmaceuticals' drug-device pain combination product Zalviso in certain countries in Europe and Australia. AcelRx will keep the rights to the product, which is under regulatory review in both the U.S. and Europe, in other territories including U.S. and Asia. The deal entitles AcelRx to $30 million up-front and about $220 million in potential milestone fees plus sales royalties.

View Full Article in:

BioWorld (free content) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care